During 2023, in Myanmar, the political situation continued to bring up many challenges in the way programmes are implemented in the country. In these times of crisis, PR-UNOPS and its implementing partners worked hard to preserve the continuation of essential health services so that the interventions were not interrupted.

By the end of 2023, 216,760 people living with HIV received antiretroviral therapy (ART) (103% of the planned target for the year). To ensure the People Living with HIV (PLHIV) access to ART, implementation approaches were adopted in line with the needs at the ground level and could continue to provide Antiretroviral Therapy to PLHIVs. 

About 548,453 (51% of target) pregnant women received HIV counseling and testing and knew their test results, and 24% of estimated HIV-positive pregnant women received antiretroviral drugs to prevent mother-to-child transmission of HIV (PMTCT) provided as part of a package of antenatal care services offered to all pregnant women at public health facilities in Myanmar. 

About 37,698 (79% of target) men who have sex with men (MSM), 42,136 (89%) female sex workers (FSW) and 29,495 (94%) people who inject drugs (PWID) were reached with HIV prevention services. In total, 36,170 (83%) FSW and 37,033 (83%) MSM underwent voluntary HIV testing and received their test results and post-test counseling. About 24,694 (65%) PWID consented to HIV testing and received their test results. 

At the end of 2023, 23,962 (65%) PWID had been enrolled in methadone maintenance therapy (MMT) in 90 MMT sites across the nation, and 68% of persons who enrolled in MMT continued the treatment for at least six months. To ensure uninterrupted MMT, implementing partners practiced take-home methadone dosages to reduce the frequency of visits to the MMT Centers by the clients while practicing physical distancing among the clients and infection control measures.

Regarding needle and syringe distribution to PWID, the equivalent of 287 (57% of target) needles and syringes per person were distributed in 2023.

In 2023, 58,541 (76% of target) of other vulnerable populations (OVP) consented to HIV testing and received their test results and post-test counseling. About 45 percent of new HIV-positive patients started isoniazid preventive therapy (IPT). Moreover, 96 percent of HIV patients were screened for TB during their last visit.